Advanced search
Publication Cover
OncoTargets and Therapy Volume 15, 2022 - Issue
Submit an article Journal homepage
79
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Efficacy and Safety of Gefitinib Plus Pemetrexed/Platinum in Advanced EGFR-Mutated Lung Adenocarcinoma Patients: A Real-World Observational Study

Rui Wang1 Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, People’s Republic of China;2 Department of Medical Oncology, Anhui Chest Hospital, Hefei, 230022, Anhui, People’s Republic of China
&
Qiang Wu1 Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, People’s Republic of China;3 Department of Pathology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, People’s Republic of ChinaCorrespondence[email protected]
Pages 31-39 | Published online: 13 Jan 2022

References

  • Pascoe HM, Knipe HC, Pascoe D, Heinze SB. The many faces of lung adenocarcinoma: a pictorial essay. J Med Imaging Radiat Oncol. 2018;62(5):654–661. doi:10.1111/1754-9485.12779
  • Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 2018;9(2):117. doi:10.1038/s41419-017-0063-y
  • Qiu Y, Shen-Tu Y. [Advance in diagnose and treatment strategies of adenocarcinoma in situ]. Zhongguo Fei Ai Za Zhi. 2017;20(9):641–644. Chinese. doi:10.3779/j.issn.1009-3419.2017.09.09
  • Kuhn E, Morbini P, Cancellieri A, Damiani S, Cavazza A, Comin CE. Adenocarcinoma classification: patterns and prognosis. Pathologica. 2018;110(1):5–11.
  • Castellanos E, Feld E, Horn L. Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer. J Thorac Oncol. 2017;12(4):612–623. doi:10.1016/j.jtho.2016.12.014
  • Hosomi Y, Morita S, Sugawara S, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol. 2020;38(2):115–123. doi:10.1200/JCO.19.01488
  • Han B, Jin B, Chu T, et al. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized controlled trial. Int J Cancer. 2017;141(6):1249–1256. doi:10.1002/ijc.30806
  • Chen X, Liu Y, Roe OD, et al. Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. PLoS One. 2013;8(3):e59314. doi:10.1371/journal.pone.0059314
  • Gao J, Li HR, Jin C, Jiang JH, Ding JY. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. Clin Transl Oncol. 2019;21(10):1287–1301. doi:10.1007/s12094-019-02075-1
  • Hainsworth JD, Waterhouse DM, Shih KC, et al. Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC). Lung Cancer. 2018;118:6–12. doi:10.1016/j.lungcan.2018.01.009
  • Noronha V, Patil VM, Joshi A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 2020;38(2):124–136. doi:10.1200/JCO.19.01154
  • Oizumi S, Sugawara S, Minato K, et al. Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations. ESMO Open. 2018;3(2):e000313. doi:10.1136/esmoopen-2017-000313
  • Lin L, Zhao J, Hu J, et al. Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience. Onco Targets Ther. 2016;9:6305–6314. doi:10.2147/OTT.S113374
  • Urata Y, Katakami N, Morita S, et al. Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. J Clin Oncol. 2016;34(27):3248–3257. doi:10.1200/JCO.2015.63.4154
  • Zhao X, Yu H, Zhao J, et al. Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer. Oncotarget. 2017;8(49):86384–86394. doi:10.18632/oncotarget.21186

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.